Martins Summer L, Curtis Kathryn M, Glasier Anna F
Division of Reproductive Health, WHO Collaborating Center in Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.
Contraception. 2006 May;73(5):445-69. doi: 10.1016/j.contraception.2006.01.003. Epub 2006 Mar 30.
This systematic review examined whether women who use combined hormonal contraception experience changes in risk of fracture or bone mineral density (BMD) that differ from nonusers. We identified 86 articles from PubMed and EMBASE (published 1966 to August 2005) that reported on fracture or BMD outcomes by use of combined hormonal contraceptives. The evidence relating to combined oral contraceptives (COCs) and fracture is inconclusive, as results from the available studies conflict. Studies of adolescent and young adult women generally found lower BMD among COC users than nonusers. Evidence for premenopausal adult women suggested no differences in BMD between COC users and nonusers. COC use in perimenopausal and postmenopausal women preserved bone mass, while nonusers lost BMD, but BMD among former COC users in this age group was the same as for never-users. Evidence for other combined hormonal methods was very limited, with one study indicating no effect of combined hormonal injectable use among premenopausal women on BMD and one study suggesting lower BMD among premenopausal users of the NuvaRing than in nonusers.
本系统评价研究了使用复方激素避孕法的女性发生骨折的风险或骨矿物质密度(BMD)变化是否与未使用者不同。我们从PubMed和EMBASE数据库(1966年至2005年8月发表)中检索到86篇文章,这些文章报告了使用复方激素避孕法后的骨折或骨密度结果。关于复方口服避孕药(COC)与骨折的证据尚无定论,因为现有研究结果相互矛盾。对青少年和年轻成年女性的研究普遍发现,使用COC者的骨密度低于未使用者。绝经前成年女性的证据表明,使用COC者和未使用者的骨密度没有差异。围绝经期和绝经后女性使用COC可保持骨量,而未使用者骨密度下降,但该年龄组曾经使用COC者的骨密度与从未使用者相同。关于其他复方激素避孕方法的证据非常有限,一项研究表明绝经前女性使用复方激素注射剂对骨密度没有影响,另一项研究表明使用NuvaRing的绝经前女性骨密度低于未使用者。